Universal leukocyte reduction: State of the art and the nature of decision making

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 2, 2002, Pages 220-222

  Sherman, Laurence A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNIZATION; BLOOD FILTRATION; BLOOD TRANSFUSION; ECONOMIC ASPECT; HUMAN; LEUKOCYTE; MEDICAL DECISION MAKING; REGULATORY MECHANISM; SAFETY; SHORT SURVEY; UNITED STATES;

DECISION MAKING; FILTRATION; HUMANS; LEUKAPHERESIS;

EID: 0036169649     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (23)

1. The case against universal WBC reduction (and for the practice of evidence-based medicine)
2. Universal WBC reduction
3. Universal 8: WBC reduction and patient advocacy
4. Universal WBC reduction: The case for and against
5. Transfusion-associated cancer recurrences and postoperative infections: Meta-analysis of randomized, controlled clinical trials
6. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: A meta-analysis of unconfounded studies
7. Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions
8. Improvement of kidney-graft survival with increased numbers of blood transfusions
9. Beneficial effect of leukocyte depletion of transfused blood on post-operative complications in patients undergoing cardiac surgery
10. Deleterious clinical effects of transfusion associated immunomodulation: Fact or fiction
11. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: The Viral Activation Transfusion Study. A randomized control trial
12. WBC reduction in RBC concentrates by prestorage filtration: Multicenter experience
13. Leukocyte reduction of blood components: Public policy and new technology
14. Selective transfusion protocols: Errors and accidents waiting to happen
15. A multicenter randomized controlled trial of transfusion requirements in critical care: Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group
16. The implications of trends in transfusion